State Street Corp Iveric Bio, Inc. Transaction History

State Street Corp

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$26.24 - $39.63 $24.8 Million - $37.5 Million	-946,285 Reduced 16.83%	4,677,893 $184 Million
Q1 2023 May 15, 2023	SELL	$18.67 - $24.56 $13.3 Million - $17.5 Million	-712,658 Reduced 11.25%	5,624,178 $137 Million
Q4 2022 Feb 14, 2023	BUY	$17.24 - $23.95 $1.59 Million - $2.21 Million	92,480 Added 1.48%	6,336,836 $136 Million
Q3 2022 Nov 15, 2022	SELL	$9.4 - $18.59 $23.4 Million - $46.3 Million	-2,489,234 Reduced 28.5%	6,244,356 $112 Million
Q2 2022 Aug 15, 2022	BUY	$9.12 - $18.9 $25.9 Million - $53.7 Million	2,843,747 Added 48.28%	8,733,590 $84 Million

Q1 2022 May 16, 2022	BUY	$12.15 - $16.83 $1.27 Million - $1.76 Million	104,692 Added 1.81%	5,889,843 $99.1 Million
Q4 2021 Feb 14, 2022	BUY	$13.83 - $18.78 $14.5 Million - $19.6 Million	1,045,693 Added 22.06%	5,785,151 $96.7 Million
Q3 2021 Nov 15, 2021	BUY	$7.07 - $17.5 $10.8 Million - $26.8 Million	1,533,832 Added 47.85%	4,739,458 $77 Million
Q2 2021 Aug 16, 2021	SELL	$5.69 - $7.17 $2.78 Million - $3.51 Million	-489,357 Reduced 13.24%	3,205,626 $20.2 Million
Q1 2021 May 17, 2021	BUY	$5.08 - $6.89 $1.42 Million - $1.93 Million	279,711 Added 8.19%	3,694,983 $22.8 Million
Q4 2020 Feb 16, 2021	BUY	$5.65 - $7.66 $12.7 Million - $17.2 Million	2,249,858 Added 193.05%	3,415,272 $23.6 Million
Q3 2020 Nov 10, 2020	BUY	$4.01 - $6.29 $1.7 Million - $2.67 Million	424,379 Added 57.27%	1,165,414 $6.57 Million
Q2 2020 Aug 14, 2020	BUY	$3.06 - $6.6 $2.27 Million - $4.89 Million	741,035 New	741,035 $3.78 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.